| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SSX7 |
| Uniprot No | Q7RTT5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-188 aa |
| 活性数据 | MNGDDAFARR PRAGAQIPEK IQKSFDDIAK YFSKKEWEKM KSLEKISYVY MKRKYEAMTK LGFKATLPPF MHNTGATDLQ GNDFDNDRNQ GNQVERPQMT FCRLQRIFPK IMPKKPAEEG NDSKGVPEAS GSQNDGKHLC PPGKPSTSEK INKTSGPKRG KHAWTHRLRE RKQLVIYEEI SDPEEDDE |
| 分子量 | 21.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SSX7蛋白的3篇参考文献的简要信息(注：SSX7研究相对较少，部分内容为示例性虚构，实际文献需通过学术数据库检索验证)：
---
1. **文献名称**：*Expression and purification of recombinant human SSX7 protein for cancer immunotherapy studies*
**作者**：Li Y, et al.
**摘要**：研究报道了通过大肠杆菌表达系统成功表达并纯化重组人SSX7蛋白。作者优化了诱导条件，采用镍柱亲和层析获得高纯度蛋白，并证实其可被SSX7特异性抗体识别，为后续癌症疫苗开发提供基础。
2. **文献名称**：*SSX7 as a novel cancer-testis antigen: Serological analysis using recombinant protein*
**作者**：Wang X, et al.
**摘要**：研究利用重组SSX7蛋白检测多种癌症患者血清中的抗体反应，发现其在黑色素瘤和肺癌中存在显著免疫原性，支持SSX7作为癌症免疫治疗靶点的潜力。
3. **文献名称**：*Structural characterization of recombinant SSX7 protein and its interaction with HLA molecules*
**作者**：Zhang R, et al.
**摘要**：通过圆二色谱和表面等离子共振技术解析重组SSX7蛋白的二级结构，证明其与HLA-A2分子结合能力，提示其在抗原呈递中的作用，为T细胞表位筛选奠定基础。
---
**提示**：以上为模拟示例，实际文献需以PubMed、Web of Science等数据库检索结果为准(可用关键词：SSX7 recombinant, SSX7 cancer antigen)。
Recombinant human SSX7 protein is a member of the SSX family (synovial sarcoma X breakpoint), which comprises nine paralogs (SSX1-9) encoded by genes clustered on the X chromosome. SSX proteins are characterized by a conserved C-terminal SSXRD (SSX repression domain) involved in transcriptional regulation and a variable N-terminal region. They are classified as cancer-testis antigens (CTAs), exhibiting restricted expression in normal tissues (primarily testis) but frequent reactivation in diverse cancers, including melanoma, breast cancer, and sarcoma. This tumor-selective expression makes SSX proteins, including SSX7. attractive targets for immunotherapy and diagnostic biomarkers.
SSX7 specifically has been less studied compared to other family members (e.g., SSX1/2 in synovial sarcoma). Recombinant SSX7 is typically produced using heterologous expression systems (e.g., E. coli or mammalian cells) with affinity-tag purification. Its structural and functional characterization remains ongoing, though its role in oncogenesis is hypothesized to involve epigenetic modulation, chromatin remodeling, or immune evasion. Current research focuses on exploring its immunogenicity for cancer vaccine development and elucidating its mechanistic contributions to malignancy. Further studies are needed to clarify its interaction networks and therapeutic potential.
×
